Bradly G Wouters, BEng, PhD

Follow Dr. Wouters:
The microenvironment of human tumours is unlike that of any normal tissue, characterized by extreme heterogeneities in nutrient supply, pH and oxygenation. These features develop as a consequence of alterations in the metabolic and proliferative status of tumour cells together with a highly irregular vascular supply. Our group is investigating the tumour microenvironment with a primary interest in understanding the cellular and molecular responses to deficiencies in oxygenation (hypoxia) and their influence on the biological behavior of tumours.

Both laboratory and clinical evidence strongly associate hypoxia with tumour development, tumour growth, metastasis and poor response to therapy. Our group has identified two important pathways that independently influence gene expression and processes of importance for hypoxic tumour cell behaviour. The first of these occurs through regulation of an important integrator of metabolic signals, the mammalian target of rapamycin (mTOR) kinase and its downstream effectors that orchestrate the initiation of protein synthesis, autophagy and apoptosis sensitivity. The second is through activation of the unfolded protein response (UPR), a program of transcriptional and translational changes that occurs as a consequence of endoplasmic reticulum (ER) stress. The UPR controls multiple downstream processes including protein production, maturation and degradation, cell metabolism and cell death. Using genetic and biochemical approaches, our lab has demonstrated the importance of these pathways in regulating gene expression, hypoxia tolerance, tumour growth and response to treatment.

Our current work is focused on:
  • Defining the molecular basis of oxygen sensing in the pathways that regulate mTOR and UPR signalling during hypoxia. We are currently studying the contribution of oxygen to protein folding and maturation in the endoplasmic reticulum.
  • Determining changes in gene expression downstream of hypoxic signalling pathways. These studies utilize high-throughput genomic methods to characterize changes in transcription, translation and protein production. Our group believes that hypoxia regulated proteins will be useful for both diagnostic and therapeutic purposes.
  • Understanding how hypoxic response pathways influence the biology of tumour cells in ways that affect patient prognosis. The signalling pathways regulated by oxygen control multiple cellular processes that are important for tumour cell growth, response to stress and survival. These include regulation of metastasis, DNA repair, autophagy and metabolism.
  • Assessing the potential of targeting hypoxic responses for improved treatment of cancer. This work involves the creation of tumour models that allow genetic manipulation of various components of hypoxic response pathways in established tumours in mice. The importance of different hypoxic response pathways is evaluated by monitoring changes in tumour metabolism, the tumour microenvironment, tumour growth and response to treatment.
  • Discovery of vulnerabilities in cancer that are manifested only within the unique microenvironment of tumours. Our group believes that cancer-associated genetic alterations influence tumour hypoxia and metabolism in ways that can be exploited for therapy and we are using high-throughput genomic tools such as RNA interference screens to identify novel molecular targets.
  • Our group also has interests in DNA repair, ubiquitin signalling, and is involved in translational research incorporating molecular targeted agents. We try to work closely with clinical colleagues to establish high-content clinical trials in radiation oncology and to translate our basic research findings into the clinic.

Related Links

Mol Pharmacol. 2019 Apr 12;:
Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR
Proc Natl Acad Sci U S A. 2019 Apr 10;:
Bassan J, Willis LM, Vellanki RN, Nguyen A, Edgar LJ, Wouters BG, Nitz M
Oncologist. 2019 Apr 05;:
Hansen AR, Tannock IF, Templeton A, Chen E, Evans A, Knox J, Prawira A, Sridhar SS, Tan S, Vera-Badillo F, Wang L, Wouters BG, Joshua AM
Nat Commun. 2019 03 29;10(1):1436
Lima-Fernandes E, Murison A, da Silva Medina T, Wang Y, Ma A, Leung C, Luciani GM, Haynes J, Pollett A, Zeller C, Duan S, Kreso A, Barsyte-Lovejoy D, Wouters BG, Jin J, Carvalho DD, Lupien M, Arrowsmith CH, O'Brien CA
Cancer Cell. 2019 Jan 09;:
Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P,...
Nat Commun. 2019 Jan 17;10(1):278
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM,...
JCI Insight. 2018 Aug 23;3(16):
Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M,...
Lancet. 2018 May 10;:
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C,...
Clin Cancer Res. 2018 Feb 23;:
Haynes J, McKee TD, Haller AC, Wang Y, Leung C, Gendoo DMA, Lima-Fernandes E, Kreso A, Wolman R, Szentgyorgyi E, Vines DC, Haibe-Kains B, Wouters BG, Metser U, Jaffray DA, Smith M, O'Brien CA
Mol Cancer Res. 2018 Feb 16;:
Ding M, van der Kwast TH, Vellanki RN, Foltz WD, McKee TD, Sonenberg N, Pandolfi PP, Koritzinsky M, Wouters BG



Professor, Department of Radiation Oncology, University of Toronto